Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial

被引：0
|
作者：
Ashina, M. [1 ]
Tepper, S. J. [2 ]
Reuter, U. [3 ]
Blumenfeld, A. M. [4 ]
Hutchinson, S. [5 ]
Xia, J. [6 ]
Miceli, R. [6 ]
Severt, L. [6 ]
Finnegan, M. [6 ]
Trugman, J. M. [6 ]
机构：
[1] Univ Copenhagen, Danish Headache Ctr, Glostrup, Denmark
[2] Geisel Sch Med Dartmouth, Hanover, NH USA
[3] Charite, Berlin, Germany
[4] Headache Ctr Southern Calif, Carlsbad, CA USA
[5] Orange Cty Migraine & Headache Ctr, Irvine, CA USA
[6] AbbVie, Madison, NJ USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0301
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [21] Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial (vo 63, pg 79, 2023)
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2024, 64 (03): : 329 - 329
  • [22] Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study
    Yasuda, Hitoshi
    Hotta, Nigishi
    Kasuga, Masato
    Kashiwagi, Atsunori
    Kawamori, Ryuzo
    Yamada, Tadaaki
    Baba, Yuko
    Alev, Levent
    Nakajo, Ko
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (01): : 100 - 108
  • [23] Evaluation of the long-term safety and tolerability of oral atogepant 60 mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the advance trial
    Klein, B.
    Miceli, R.
    Severt, L.
    McAllister, P.
    Mechtler, L.
    McVige, J.
    Diamond, M.
    Marmura, M. J.
    Guo, H.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [24] ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB): DOUBLE-BLIND 52-WEEK RESULTS FROM AN EXTENSION STUDY OF THE INTERNATIONAL PHASE 3 TRIAL (EMPOWUR)
    Staskin, David
    Frankel, Jeffrey
    Varano, Susann
    Shortino, Denise
    Jankowich, Rachael
    Mudd, Paul
    JOURNAL OF UROLOGY, 2020, 203 : E453 - E453
  • [25] Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: A 52-week open-label study
    Peters-Strickland T.
    Baker R.A.
    McQuade R.D.
    Jin N.
    Eramo A.
    Perry P.
    Johnson B.R.
    Duca A.
    Sanchez R.
    npj Schizophrenia, 1 (1):
  • [26] Once-daily oral trovafloxacin in the treatment of diabetic foot infections - Results of an open-label, noncomparative, multicentre trial
    Daniel, R
    DRUGS, 1999, 58 (Suppl 2) : 291 - 292
  • [27] Evaluation of the long-term safety and tolerability of oral atogepant 60 mg once daily for preventive treatment of migraine: a phase 3, 40-week, multi-center extension to the advance trial
    Klein, B.
    Miceli, R.
    Severt, L.
    McAllister, P.
    Mechtler, L.
    McVige, J.
    Diamond, M.
    Marmura, M. J.
    Guo, H.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 235 - 235
  • [28] Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52Week, Open-Label Extension Study
    Ailani, J.
    Kudrow, D.
    Smith, T.
    Lipton, R.
    Thiry, A. C.
    Jensen, C. M.
    Kamen, L.
    Coric, V.
    Croop, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [29] Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
    Lipton, Richard B.
    Tepper, Stewart J.
    Silberstein, Stephen D.
    Kudrow, David
    Ashina, Messoud
    Reuter, Uwe
    Dodick, David W.
    Zhang, Feng
    Rippon, Gregory A.
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2021, 41 (01) : 6 - 16
  • [30] Long-Term Safety and Efficacy of Donepezil in Patients with Dementia with Lewy Bodies: Results from a 52-Week, Open-Label, Multicenter Extension Study
    Ikeda, Manabu
    Mori, Etsuro
    Kosaka, Kenji
    Iseki, Eizo
    Hashimoto, Mamoru
    Matsukawa, Noriyuki
    Matsuo, Kazutaka
    Nakagawa, Masaki
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2013, 36 (3-4) : 229 - 241
12345